Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CLLS Cellectis
- Stocks
- Healthcare
- NASDAQ: CLLS
Price (delayed)
$1.47
Market cap
$106.27M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.67
Enterprise value
-$28.6M
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene
Highlights
The company's gross profit rose by 11% QoQ
The revenue is up by 11% from the previous quarter
CLLS's net income has dropped by 65% since the previous quarter but it is up by 7% year-on-year
The company's EPS has shrunk by 63% QoQ but it rose by 40% YoY
Key stats
What are the main financial stats of CLLS
Market
Valuations
Earnings
Shares outstanding
72.29M
Market cap
$106.27M
Enterprise value
-$28.6M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.91
Price to sales (P/S)
2.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.52
Revenue
$54.75M
Gross profit
$54.75M
Operating income
-$52.84M
Net income
-$60.53M
EBIT
-$31.55M
EBITDA
-$11.34M
Free cash flow
$26.38M
Per share
Balance sheet
Liquidity
EPS
-$0.67
EPS diluted
-$0.44
Free cash flow per share
$0.26
Book value per share
$1.61
Revenue per share
$0.55
TBVPS
$3.63
Total assets
$364.09M
Total liabilities
$247.88M
Debt
$108.82M
Equity
$116.2M
Working capital
$109.26M
Debt to equity
0.94
Current ratio
1.67
Quick ratio
2.35
Net debt/EBITDA
11.9
Margins
Efficiency
Dividend
EBITDA margin
-20.7%
Gross margin
100%
Net margin
-110.6%
Operating margin
-96.5%
Return on assets
-15.6%
Return on equity
-46.1%
Return on invested capital
-24.2%
Return on capital employed
-15.7%
Return on sales
-57.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLLS stock price
How has the Cellectis stock price performed over time
Intraday
-3.31%
1 week
-6.96%
1 month
0.68%
1 year
-49.31%
YTD
-18.33%
QTD
18.55%
Financial performance
How have Cellectis's revenue and profit performed over time
Revenue
$54.75M
Gross profit
$54.75M
Operating income
-$52.84M
Net income
-$60.53M
Gross margin
100%
Net margin
-110.6%
Cellectis's operating margin has soared by 88% YoY and by 20% from the previous quarter
The company's net margin has surged by 79% YoY but it fell by 48% QoQ
CLLS's net income has dropped by 65% since the previous quarter but it is up by 7% year-on-year
The company's operating income rose by 44% YoY and by 11% QoQ
Price vs fundamentals
How does CLLS's price correlate with its fundamentals
Growth
What is Cellectis's growth rate over time
Valuation
What is Cellectis stock price valuation
P/E
N/A
P/B
0.91
P/S
2.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.52
The company's EPS has shrunk by 63% QoQ but it rose by 40% YoY
The P/B is 43% less than the 5-year quarterly average of 1.6 and 9% less than the last 4 quarters average of 1.0
CLLS's equity is up by 28% year-on-year but it is down by 11% since the previous quarter
The price to sales (P/S) is 78% lower than the 5-year quarterly average of 12.5 and 44% lower than the last 4 quarters average of 4.8
The revenue is up by 11% from the previous quarter
Efficiency
How efficient is Cellectis business performance
CLLS's return on invested capital has dropped by 122% since the previous quarter and by 47% year-on-year
The company's return on sales has shrunk by 87% QoQ but it has surged by 74% YoY
CLLS's ROA has dropped by 64% since the previous quarter but it is up by 33% year-on-year
The return on equity has dropped by 57% since the previous quarter but it has grown by 39% year-on-year
Dividends
What is CLLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLLS.
Financial health
How did Cellectis financials performed over time
CLLS's total assets is 47% greater than its total liabilities
CLLS's quick ratio is up by 9% year-on-year but it is down by 2.1% since the previous quarter
Cellectis's total liabilities has decreased by 6% YoY
The company's debt is 6% lower than its equity
CLLS's equity is up by 28% year-on-year but it is down by 11% since the previous quarter
CLLS's debt to equity is down by 27% year-on-year but it is up by 12% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.